Does Metformin affect ER, PR, IGF-1R, β-catenin and PAX-2 expression in women with diabetes mellitus and endometrial cancer?

Table 3 Mean percentage (± SD) of positive immunohistochemically stained cells (IGF-1R and β-catenin) and mean SCORE results (ER, PR and PAX-2) in patient subgroups

	PR score	ER score	PAX-2 score	IGF-1R	β-catenin (membranous)
EC + diabetes (n = 48)	6.85 ± 1.76	6.91 ± 1.51	3.58 ± 2.42	36.79 ± 26.73	86.87 ± 19.17
M in mono- and polytherapy (n = 32)	6.78 ± 2.01	6.71 ± 1.67	3.37 ± 2.41	36.59 ± 24.49	83.75 ± 21.28
M in monotherapy (n = 22)	6.86 ± 1.83	6.77 ± 1.15	3.5 ± 2.64	36.41 ± 26.16	84.54 ± 20.23
I + SD (n = 16)	7.0 ± 1.15	7.31 ± 1.07	4.37 ± 2.02	37.18 ± 31.72	93.12 ± 12.36
I in monotherapy (n = 10)	7.1 ± 1.28	7.8 ± 0.42	4.2 ± 2.34	33.5 ± 28.96	97.0 ± 6.32
Control (n = 38)	6.39 ± 2.23	6.28 ± 2.17	3.34 ± 2.31	18.29 ± 27.27	87.5 ± 24.40

EC- endometrial cancer, M- metformin, I- insulin, SD- sulfonylurea derivatives, I + SD- Due to small number of patients receiving sulfonylurea derivatives in monotherapy (n = 6) we have analyzed this subgroup together with patients treated with insulin.

ISSN: 1758-5996